JP6421128B2 - リアソータントインフルエンザａウイルス - Google Patents

リアソータントインフルエンザａウイルス Download PDF

Info

Publication number
JP6421128B2
JP6421128B2 JP2015544499A JP2015544499A JP6421128B2 JP 6421128 B2 JP6421128 B2 JP 6421128B2 JP 2015544499 A JP2015544499 A JP 2015544499A JP 2015544499 A JP2015544499 A JP 2015544499A JP 6421128 B2 JP6421128 B2 JP 6421128B2
Authority
JP
Japan
Prior art keywords
virus
segment
influenza
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015544499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501020A5 (enExample
JP2016501020A (ja
Inventor
ピーター メイソン，
ピーター メイソン，
フィリップ ラルフ ドルミッチャー，
フィリップ ラルフ ドルミッチャー，
ハイディ トルシェイム，
ハイディ トルシェイム，
ピラダ スッパピパット，
ピラダ スッパピパット，
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
シンセティック ジェノミクス ヴァクシンズ， インコーポレーテッド
シンセティック ジェノミクス ヴァクシンズ， インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー, シンセティック ジェノミクス ヴァクシンズ， インコーポレーテッド, シンセティック ジェノミクス ヴァクシンズ， インコーポレーテッド filed Critical ノバルティス アーゲー
Publication of JP2016501020A publication Critical patent/JP2016501020A/ja
Publication of JP2016501020A5 publication Critical patent/JP2016501020A5/ja
Application granted granted Critical
Publication of JP6421128B2 publication Critical patent/JP6421128B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2015544499A 2012-12-03 2013-12-02 リアソータントインフルエンザａウイルス Active JP6421128B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261732809P 2012-12-03 2012-12-03
US61/732,809 2012-12-03
PCT/EP2013/075294 WO2014086732A2 (en) 2012-12-03 2013-12-02 Influenza virus reassortment

Publications (3)

Publication Number Publication Date
JP2016501020A JP2016501020A (ja) 2016-01-18
JP2016501020A5 JP2016501020A5 (enExample) 2017-01-19
JP6421128B2 true JP6421128B2 (ja) 2018-11-07

Family

ID=49713076

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015544499A Active JP6421128B2 (ja) 2012-12-03 2013-12-02 リアソータントインフルエンザａウイルス

Country Status (11)

Country Link
US (3) US9708585B2 (enExample)
EP (1) EP2925356A2 (enExample)
JP (1) JP6421128B2 (enExample)
KR (1) KR20150110494A (enExample)
CN (1) CN105120893B (enExample)
AU (2) AU2013354219A1 (enExample)
BR (1) BR112015012380A2 (enExample)
CA (1) CA2893429A1 (enExample)
HK (1) HK1214959A1 (enExample)
MX (1) MX2015006927A (enExample)
WO (1) WO2014086732A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013354219A1 (en) * 2012-12-03 2015-07-02 Novartis Ag Reassortant influenza a viren
WO2016172588A1 (en) * 2015-04-24 2016-10-27 Andrew Cox Attenuated influenza vaccines and uses thereof
AU2016281904B2 (en) 2015-06-26 2022-08-11 Seqirus UK Limited Antigenically matched influenza vaccines
GB201602535D0 (en) * 2016-02-12 2016-03-30 Univ Edinburgh Improved flu vaccine yield
WO2019044636A1 (ja) * 2017-08-28 2019-03-07 一般財団法人阪大微生物病研究会 リアソータントインフルエンザウイルスの段階的作出方法
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
CN111315407B (zh) * 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
KR101954904B1 (ko) 2018-10-15 2019-03-06 남종규 복층의 태양광 설치 구조
CN111647610B (zh) * 2020-06-02 2021-09-03 扬州大学 一种互换ha和ns1缺失基因包装信号的h9n2亚型禽流感病毒及其构建方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
EP1098961B1 (en) 1998-06-12 2008-01-16 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
AR025750A1 (es) 1999-09-24 2002-12-11 Smithkline Beecham Biolog Vacunas
WO2001064846A1 (fr) 2000-03-03 2001-09-07 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Cellule utilisable pour culture sans serum et culture en suspension, et procede de production de virus pour vaccin utilisant cette cellule
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US20040071734A1 (en) 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
WO2002067983A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Novel vaccine
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
WO2005097181A1 (en) 2004-04-05 2005-10-20 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
US20080254067A1 (en) 2004-05-20 2008-10-16 Id Biomedical Corporation Process for the Production of an Influenza Vaccine
CN103555670B (zh) 2004-12-23 2015-08-12 米迪缪尼有限公司 用于病毒增殖的非致瘤性mdck细胞系
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
CA2613283A1 (en) 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Methods and compositions for expressing a heterologous protease
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
ES2359214T5 (es) 2005-11-01 2014-10-08 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual por tratamiento con beta-propiolactona
BRPI0618254A2 (pt) 2005-11-04 2011-08-23 Novartis Vaccines & Diagnostic emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
JP2009532352A (ja) * 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
JP5491173B2 (ja) 2006-04-19 2014-05-14 メディミューン，エルエルシー イヌ細胞中でマイナス鎖ウイルスｒｎａを発現させるための方法および組成物
PT2086582E (pt) 2006-10-12 2013-01-25 Glaxosmithkline Biolog Sa Vacina compreendendo uma emulsão adjuvante óleo em água
CN101553252A (zh) 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
WO2008157419A2 (en) * 2007-06-13 2008-12-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic peptides of influenza virus
EP2045323A1 (en) 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
ES2675771T3 (es) * 2008-12-16 2018-07-12 Ology Bioservices, Inc. Producción de vacunas contra el virus de la gripe
EP2233152A1 (en) 2009-03-24 2010-09-29 Avir Green Hills Biotechnology Research Development Trade Ag High growth reassortant influenza A virus
EP2401384B1 (en) 2009-05-21 2012-10-03 Novartis AG Reverse genetics using non-endogenous pol i promoters
EP2448598B1 (en) * 2009-06-25 2016-03-30 MedImmune, LLC Swine influenza hemagglutinin variants
CN102666860B (zh) 2009-07-31 2015-06-17 诺华股份有限公司 反向遗传系统
JP5876036B2 (ja) * 2010-05-21 2016-03-02 ノバルティス アーゲー インフルエンザウイルス再集合方法
FR2962739B1 (fr) * 2010-07-13 2014-01-31 Univ Claude Bernard Lyon Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza
AU2013354219A1 (en) * 2012-12-03 2015-07-02 Novartis Ag Reassortant influenza a viren

Also Published As

Publication number Publication date
AU2018232956B2 (en) 2020-10-01
US20150315548A1 (en) 2015-11-05
EP2925356A2 (en) 2015-10-07
US20200155666A1 (en) 2020-05-21
KR20150110494A (ko) 2015-10-02
CN105120893B (zh) 2018-11-13
BR112015012380A2 (pt) 2017-09-12
CN105120893A (zh) 2015-12-02
US20170326227A1 (en) 2017-11-16
US9708585B2 (en) 2017-07-18
AU2013354219A1 (en) 2015-07-02
HK1214959A1 (zh) 2016-08-12
WO2014086732A2 (en) 2014-06-12
WO2014086732A3 (en) 2014-07-24
JP2016501020A (ja) 2016-01-18
AU2018232956A1 (en) 2018-10-11
CA2893429A1 (en) 2014-06-12
US10500266B2 (en) 2019-12-10
WO2014086732A8 (en) 2018-12-06
MX2015006927A (es) 2016-02-05

Similar Documents

Publication Publication Date Title
JP6279503B2 (ja) インフルエンザウイルスの再集合
JP6082483B2 (ja) インフルエンザウイルス再集合方法
JP6525469B2 (ja) インフルエンザｂ型ウイルス再集合
JP6421128B2 (ja) リアソータントインフルエンザａウイルス
JP2016521553A (ja) インフルエンザウイルス再集合
JP5836266B2 (ja) 非内因性ｐｏｌＩプロモーターを使用した逆遺伝学
JP2011522874A (ja) 季節性および汎流行性の防御のための混合インフルエンザワクチン
JP2016104004A (ja) ウイルスレスキューのための改善された逆遺伝学
JP2016506724A (ja) インフルエンザウイルスの再集合
JP2012517416A (ja) 増加した量のｈ３抗原を含むインフルエンザワクチン
AU2014203051B2 (en) Influenza Virus Reassortment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161202

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180731

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180921

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181015

R150 Certificate of patent or registration of utility model

Ref document number: 6421128

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250